drugset / Trial / NCT01322815

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

NCT01322815

Phase 2 Terminated 11 enrolled Georgetown University GlobeImmune · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time. This study is also being done to measure the immune response to GI-4000. Study drug will be given in addition to a standard of care which is a standard therapy given to patients with your type of cancer (colon).

Timeline

Start
2010-10
Primary completion
2014-09
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GI-4000 Vaccine 40 unknown Other
Background Bevacizumab Monoclonal antibody
Background Irinotecan Small molecule
Background Leucovorin Small molecule
Background Oxaliplatin Small molecule
Background fluorouracil Small molecule

Indications